1. Home
  2. TR vs AGIO Comparison

TR vs AGIO Comparison

Compare TR & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tootsie Roll Industries Inc.

TR

Tootsie Roll Industries Inc.

HOLD

Current Price

$43.01

Market Cap

3.1B

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$34.18

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TR
AGIO
Founded
1896
2007
Country
United States
United States
Employees
2100
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
1.6B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
TR
AGIO
Price
$43.01
$34.18
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$37.63
AVG Volume (30 Days)
117.9K
773.2K
Earning Date
04-23-2026
04-30-2026
Dividend Yield
0.84%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
N/A
$71.05
Revenue Next Year
N/A
$163.65
P/E Ratio
$32.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.13
$22.24
52 Week High
$44.27
$46.00

Technical Indicators

Market Signals
Indicator
TR
AGIO
Relative Strength Index (RSI) 61.31 76.02
Support Level $40.07 $32.68
Resistance Level $43.37 $43.72
Average True Range (ATR) 1.26 1.28
MACD 0.06 0.59
Stochastic Oscillator 75.14 74.81

Price Performance

Historical Comparison
TR
AGIO

About TR Tootsie Roll Industries Inc.

Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: